44 results on '"Borchmann, Sven"'
Search Results
2. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
3. Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV‐independent major determinant of microenvironment composition in classic Hodgkin lymphoma.
4. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA
5. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
6. An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer
7. S236: HIGH-BREADTH SEQUENCING OF CIRCULATING TUMOR DNA IDENTIFIES NOVEL CLASSIFICATION OF HODGKIN LYMPHOMA
8. P1384: MULTI-EFFECTOR IMMUNE CELL RETARGETING USING A BISPECIFIC SINGLE-CHAIN VARIABLE FRAGMENT LIBRARY IN AGGRESSIVE B CELL LYMPHOMAS
9. P1209: PERIPHERAL BLOOD CTDNA-SEQUENCING ENABLES PREDICTION OF OUTCOMES IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING A DYNAMIC RISK MODEL
10. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
11. Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma
12. Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing
13. P046: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
14. P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
15. P059: Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma
16. Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors
17. EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
18. Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment
19. Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma
20. Abstract LBA010: Therapeutic stimulation of nucleic acid receptor RIG-I enhances efficacy of kinase inhibitor treatment in oncogene-driven tumors
21. Additional file 2 of An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer
22. Additional file 4 of An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer
23. Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
24. An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer
25. Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication
26. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC
27. Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
28. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
29. Suicide in European Hodgkin Lymphoma Patients
30. Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
31. Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma
32. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
33. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
34. Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
35. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
36. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer
37. Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma
38. Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude
39. Seasonal Differences in Incidence and Survival of Hodgkin Lymphoma Depend on Geographic Location of Diagnosis
40. Suicide in European Hodgkin Lymphoma Patients
41. Thrombosis in Hodgkin Lymphoma Patients: Incidence, Time Points, Risk Factors and Impact of Stage and Treatment
42. Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis.
43. Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.
44. Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.